Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Toyocamycin (Vengicide) is an adenosine analog produced by Actinomycete, acts as an XBP1 inhibitor, inhibits IRE1α-induced ATP-dependent XBP1 mRNA cleavage (IC50: 80 nM). Toyocamycin induces apoptosis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 39.00 | |
10 mg | In stock | $ 59.00 | |
25 mg | In stock | $ 115.00 | |
50 mg | In stock | $ 213.00 | |
100 mg | In stock | $ 372.00 | |
500 mg | In stock | $ 869.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 43.00 |
Description | Toyocamycin (Vengicide) is an adenosine analog produced by Actinomycete, acts as an XBP1 inhibitor, inhibits IRE1α-induced ATP-dependent XBP1 mRNA cleavage (IC50: 80 nM). Toyocamycin induces apoptosis. |
Targets&IC50 | XBP1:80 nM |
Synonyms | Vengicide |
Molecular Weight | 291.26 |
Formula | C12H13N5O4 |
CAS No. | 606-58-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (343.34 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Toyocamycin 606-58-6 Apoptosis Cell Cycle/Checkpoint Microbiology/Virology Others IRE1 Antibiotic Antifungal RNA synthesis CDK mRNA cleavage epigenetics CDK9 inhibitor Cyclin dependent kinase molecular docking reactive oxygen species CDKs RNA Pol II phosphorylation Vengicide Inositol requiring enzyme 1 Fungal Inhibitor adenosine analog drug screening ribosome function inhibit extracellular signal-regulated kinases cancer inhibitor